A newly identified immune checkpoint protein may lead to future cancer therapies
Penn Medicine researchers have found that knocking out a T cell’s CD5 gene greatly enhances the cell’s anticancer activity in a variety of preclinical cancer models.
Mattie Chaya Kimberly “Kimi” Klauser (in hat second from right) with her bandmates.
(Image: Courtesy of Penn Medicine News)
Gender-affirming care at Penn Medicine: A future ‘not in the shadows’
The Penn Medicine Program for LGBTQ+ Health and gender-affirming care at Penn Medicine has helped Mattie Chaya Kimberly “Kimi” Klauser and others get the right care in an open, safe, and nurturing environment.
Study reveals inequities in access to transformative CAR T cell therapy
Penn Medicine researchers have assessed the percentage of patients from minority health populations and reveal inequities in access to transformative CAR T cell therapy.
Gregory L. Beatty is an associate professor of hematology-oncology and member of Penn Medicine’s Abramson Cancer Center.
(Image: Courtesy of Penn Medicine News)
Mapping pancreatic cancer to improve immunotherapy
Gregory L. Beatty, an associate professor of hematology-oncology and member of Penn Medicine’s Abramson Cancer Center, and his team focus on improving immunotherapy for pancreatic cancer.
‘Dual target’ cell therapy appears to shrink brain tumors
Early Penn Medicine trial results show that targeting two tumor-associated proteins in patients with recurrent glioblastoma may be a promising step toward developing cell therapies for solid tumors.
